
CLAIMS

What is claimed is:


1. Use of a compound having the formula



, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating colon carcinoma in combination with a PD-1 signaling inhibitor.

~~1. or a pharmaceutically acceptable salt thereof, A method of in the manufacture of a medicament for treating cancercolon carcinoma in a subject in need thereof, comprising administering to the subject:~~

~~(a) a compound of Formula I:~~



~~(I)~~

~~or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group and A is optionally substituted phenyl, pyridyl or pyrimidyl; and~~


~~(b)~~ wherein said medicament is to be administered in combination with a PD-1 signaling inhibitor~~, wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective~~.

~~2. The method of claim 1, wherein R is $R_1C(O)$, wherein R_1 is substituted or unsubstituted C_1-C_{24} alkyl; substituted or unsubstituted C_2-C_{24} alkenyl, preferably C_2-C_{10} alkenyl, and more preferably C_2-C_6 alkenyl; substituted or unsubstituted C_2-C_{24} alkynyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl.~~

~~3. The method of claim 1, wherein R is hydrogen or acetyl.~~


4. The method of claim 3, wherein R is hydrogen.

5. The method of any one of claims 1 to 4, wherein A is selected from the groups below:




.


6. The method of claim 1, wherein the compound of Formula I is selected from:



,




, and



;

or a pharmaceutically acceptable salt thereof.

~~7. The method of claim 1, wherein the compound of Formula I is represented by the formula:~~



~~or a pharmaceutically acceptable salt thereof.~~

2~~8~~. The ~~method~~use of ~~any one of~~ claim~~s~~ 1~~ to 7~~, wherein the PD-1 signaling inhibitor is an inhibitor of one or more of PD-1, PD-L1, and PD-L2.

9~~3~~. The ~~method~~use of claim 8~~2~~, wherein the PD-1 signaling inhibitor inhibits PD-1 or PD-L1.

10~~4~~. The ~~method~~use of claim 8~~3~~, wherein the PD-1 signaling inhibitor is pembrolizumab, nivolumab, atelolizumab, avelumab, durvalumab or pidilizumab.

11~~5~~. The ~~method~~use of claim 10~~4~~, wherein the PD-1 signaling inhibitor is pembrolizumab or nivolumab.

~~12. The method of any one of claims 1 to 11, wherein:~~

~~(a) the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered simultaneously to the subject as separate compositions; or~~

~~(b) the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered sequentially to the subject as separate compositions.~~

~~13. The method of any one of claims 1 to 11, wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in a single composition.~~

~~14. The method of any one of claims 1 to 13, wherein the cancer is a hematological cancer.~~

~~15. The method of claim 14, wherein the cancer is a leukemia or a lymphoma.~~

~~16. The method of claim 14, wherein the lymphoma is a B-cell lymphoma, a T cell lymphoma or a NK cell lymphoma.~~

~~17. The method of claim 14, wherein the lymphoma is diffuse large cell B cell lymphoma.~~


~~18. The method of claim 10, wherein the cancer is a hematological cancer.~~

~~19. The method of claim 17, wherein the cancer is a leukemia or a lymphoma.~~

~~20. The method of claim 17, wherein the lymphoma is a B-cell lymphoma, a T cell lymphoma or a NK cell lymphoma.~~

~~21~~6. A pharmaceutical composition for use in treating colon carcinoma, comprising:

(a) a compound of the formula ~~Formula I:~~



~~(I)~~

or a pharmaceutically acceptable salt thereof~~, wherein R is hydrogen or an acyl group and A is optionally substituted phenyl, pyridyl or pyrimidyl~~;

(b) a PD-1 signaling inhibitor; and

(c) a pharmaceutically acceptable carrier or excipient.

7. The pharmaceutical composition of claim 6, wherein the PD-1 signaling inhibitor is an inhibitor of one or more of PD-1, PD-L1, and PD-L2.


8. The pharmaceutical composition of claim 6, wherein the PD-1 signaling inhibitor is pembrolizumab, nivolumab, atelolizumab, avelumab, durvalumab or pidilizumab.

~~22. The pharmaceutical composition of claim 21, wherein R is $R_1C(O)$, wherein R_1 is substituted or unsubstituted C_1-C_{24} alkyl; substituted or unsubstituted C_2-C_{24} alkenyl, preferably C_2-C_{10} alkenyl, and more preferably C_2-C_6 alkenyl; substituted or unsubstituted C_2-C_{24} alkynyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl.~~


~~23. The pharmaceutical composition of claim 22, wherein R is hydrogen or acetyl.~~


~~24. The pharmaceutical composition of claim 23, wherein R is hydrogen.~~

~~25. The pharmaceutical composition of any one of claims 20 to 23, wherein A is selected from the groups below:~~




~~26. The pharmaceutical composition of claim 20, wherein the compound of Formula I is selected from:~~






and



—

~~or a pharmaceutically acceptable salt thereof.~~

~~27. The pharmaceutical composition of claim 20, wherein the compound of Formula I is represented by the formula:~~



~~289~~. The pharmaceutical composition of any one of claims ~~206~~ to ~~268~~, in the form of a tablet or capsule.